Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood First Edition Paper, prepublished online March 13, 2008; DOI 10.1182/blood-2007-10-119552.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Stefanescu, R.
Right arrow Articles by Laurence, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stefanescu, R.
Right arrow Articles by Laurence, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted October 23, 2007
Accepted February 29, 2008

Synergistic interactions between interferon-{gamma} and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis

Radu Stefanescu, Dustin Bassett, Rozbeh Modarresi, Francisco Santiago, Mohamad Fakruddin, and Jeffrey Laurence*

Dept. of Medicine, Division of Hematology-Oncology, Weill Medical College-Cornell, New York, NY, United States
Global TB Vaccine Foundation, AERAS, Rockville, MD, United States

* Corresponding author; email: jlaurenc{at}med.cornell.edu.

Microvascular endothelial cell (MVEC) injury coupled to progression of platelet microthrombi facilitated by ADAMTS13 deficiency is characteristic of idiopathic and human immunodeficiency virus (HIV)-linked thrombotic thrombocytopenic purpura (TTP). Cytokines capable of inducing MVEC apoptosis in vitro are upregulated in both TTP and HIV infection. However, the concentrations of these cytokines required to elicit EC apoptosis in vitro are 2-3 log-fold greater than present in patient plasmas. We report that clinically relevant levels of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and interferon (IFN)-{gamma} act in synergy to induce apoptosis in dermal MVEC, but have no effect on large vessel EC or pulmonary MVEC. This reflects the tissue distribution of TTP lesions in vivo. Sensitivity to TTP plasma or TRAIL + IFN-{gamma} is paralleled by enhanced ubiquitination of the caspase 8 regulator c-FLIP, targeting it for proteasome degradation. c-FLIP silencing with anti-FLIP siRNA in pulmonary MVEC rendered them susceptible to TTP plasma and cytokine-mediated apoptosis, while upregulation of c-FLIP by gene transfer partially protected dermal MVEC from such injury. TTP plasma-mediated apoptosis appears to involve cytokine-induced acceleration of c-FLIP degradation, sensitizing cells to TRAIL-mediated caspase 8 activation and cell death. Suppression of TRAIL or modulation of immunoproteasome activity may have therapeutic relevance in TTP.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020